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Abstract: Peptoids (oligo N-substituted glycines) are peptide analogues, which can be designed to
mimic host antimicrobial peptides, with the advantage that they are resistant to proteolytic degrada-
tion. Few studies on the antimicrobial efficacy of peptoids have focused on Gram negative anaerobic
microbes associated with clinical infections, which are commonly recalcitrant to antibiotic treatment.
We therefore studied the cytotoxicity and antibiofilm activity of a family of peptoids against the Gram
negative obligate anaerobe Fusobacterium nucleatum, which is associated with infections in the oral
cavity. Two peptoids, peptoid 4 (NaeNpheNphe)4 and peptoid 9 (NahNspeNspe)3 were shown to be
efficacious against F. nucleatum biofilms at a concentration of 1 µM. At this concentration, peptoids 4
and 9 were not cytotoxic to human erythrocytes or primary human gingival fibroblast cells. Peptoids
4 and 9 therefore have merit as future therapeutics for the treatment of oral infections.
Keywords: antimicrobial; biofilms; cytotoxicity; peptidomimetic; peptoid; targeted therapeutic
1. Introduction
Currently, a plethora of different management strategies exists for the treatment of
Gram negative anaerobic infections in the oral cavity, including the administration of
systemic antibiotics. With the global rise in antibiotic resistance, there has been a drive to
find alternatives to antibiotics. In recent years, short cationic host defence peptides have
been investigated as alternatives to antibiotics, having both antimicrobial and immunomod-
ulatory functions [1–3]. Although viewed as nature’s antibiotics, these peptides generally
target bacterial cell membranes [1] rather than the specific metabolic pathways targeted
by conventional antibiotics. Importantly, this mechanism of action has the advantage that
bacteria are less likely to develop resistance [1]. However, the therapeutic translation
of peptide treatments has been limited by their cost [4], potential toxicity [1] and their
susceptibility to proteolytic degradation [1,5,6].
The design and synthesis of oligo-N-substituted glycines to generate peptidomimetics
termed peptoids [7–9] is one potential solution to proteolytic instability, involving mod-
ification of the peptide backbone. Whereas peptides have their side chain (R), attached
to the α-carbon atom, the R group in peptoids is attached to the amide nitrogen, thus
rendering peptoids stable to proteolytic degradation [10]. Peptoids have been shown
to be very effective antimicrobials against a variety of different microbes [10–19]. Sev-
eral families of antimicrobial peptoids have been developed, including those based on
repeating subunits [10,20]. One family of amphipathic peptoids, previously studied by
our research group [10], was based around an NxNyNy subunit, repeated two, three or
four times. Within each subunit, Nx was a positively charged lysine-type amine with
Molecules 2021, 26, 4741. https://doi.org/10.3390/molecules26164741 https://www.mdpi.com/journal/molecules
Molecules 2021, 26, 4741 2 of 10
various side chains (Nah = N-(6-aminohexyl)glycine, NLys = N-(4-aminobutyl)glycine or
Nae = N-(2-aminoethyl)glycine), and Ny was either the chiral aromatic monomer Nspe
(N-(S-phenylethyl) glycine) or the achiral Nphe (N-Benzylglycine) [10]. The chiral peptoid
monomer Nspe has been shown to help stabilise the helical secondary structure of the
linear peptoid, which is known to improve anti-microbial activity [15]. Several of the
peptoids from this family (peptoids 1–9, Figure 1) have been shown to be effective against
Escherichia coli biofilms [10], commonly associated with medical device infections.




Figure 1. Sequences and pictorial representation of peptoids (1–9) analysed in the current 
study. Peptoid sequences were designed around an NxNyNy subunit, repeated three or four 
times (9- or 12-residue peptoids, respectively). Within the NxNyNy subunit, Nx is a positively 
charged lysine-type amine with various side chain lengths; NLys N-(4-aminobutyl) glycine, 
Nae N-(2-aminoethyl)glycine) or (Nah N-(6-aminohexyl) glycine, whereas Ny is either the 
chiral aromatic building block; Nspe N-(S-phenylethyl)glycine or the achiral Nphe 
N-benzylglycine. 
2. Results 
2.1. Haemolytic Effect of Peptoids on Human Erythrocytes 
Peptoids 2 and 8 lysed similar (peptoid 2) or higher (peptoid 8) percentages of 
human erythrocytes compared to the Triton x-100 positive control (Figure 2) and 
were not studied further. The remaining peptoids displayed variable haemolytic ac-
Figure 1. Sequences and pictorial representation of peptoids (1–9) analysed in the current study.
Peptoid sequ nc s were designed around an NxNyNy subunit, repeated three or four times (9- or 12-
residue p toids, resp ctively). Within the NxNyNy subunit, x i a posi iv ly charged lysine-type
amin with various side chain lengths; NLys N-(4-aminobutyl) glycine, Nae N-(2-aminoethyl)glycine)
or (Nah N-(6-aminohexyl) glycine, whereas Ny is either the chiral aromatic building block; Nspe
N-(S-phenylethyl)glycine or the achiral Nphe N-benzylglycine.
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The antimicrobial efficacy of peptoids has not previously focused on Gram negative
obligately anaerobic microorganisms. Fusobacterium nucelatum is a Gram negative obligate
anaerobe that plays an important role in the developing oral plaque biofilm, particularly in
the transition from the commensal Gram positive aerobes found in healthy mouths to the
pathological Gram negative anaerobes associated with the pathogenesis of infections such
as periodontal disease and peri-implantitis in the oral cavity [21]. With periodontal disease
reported to affect 45% of the population [22] and peri-implantitis reported to affect between
1–47% of dental implants [23], new treatments for oral anaerobic infections are currently in
demand. In the development of oral biofilms, F. nucleatum tends to act as a ‘bridging’ microbe,
facilitating the adherence of more pathogenic Gram negative anaerobes (late colonisers) to the
commensal microbes (early colonisers). Treatment and eradication of F. nucleatum could limit
colonisation by more pathogenic microbes and therefore limit development of infection.
Acute, Gram negative anaerobic infections in the oral cavity may require the use of
antibiotics, which have been reported to be over-prescribed by dentists [24]. Antibiotic resis-
tance is now emerging in oral pathogens, and it was shown that 16% of F. nucleatum strains
are resistant to amoxicillin and 36% of F. nucleatum strains are resistant to clindamycin [25].
As possible alternatives to the use of antibiotics, our research group and others have fo-
cused on peptide-based antimicrobials with efficacy against F. nucleatum [26–28]. Peptides
from the African volcano frog Xenopus amieti (Pipidae), were previously shown by us to
have antimicrobial activity against F. nucleatum [26]. More recently, ultra-short peptide
hydrogels [27] and a peptide-loaded poloxamer-based microemulsion gel [28] were also
shown to be efficacious against F. nucleatum. Moreover, clinical trials have reported efficacy
for peptide-based treatments of oral infections [29].
The aim of this research was to determine the cytotoxicity of a series of peptoids
against human erythrocytes and human primary cells, and to assess their antibiofilm
efficacy against F. nucleatum. To our knowledge, this is the first report to study peptoid
efficacy against an anaerobic microbe.
2. Results
2.1. Haemolytic Effect of Peptoids on Human Erythrocytes
Peptoids 2 and 8 lysed similar (peptoid 2) or higher (peptoid 8) percentages of human
erythrocytes compared to the Triton x-100 positive control (Figure 2) and were not studied
further. The remaining peptoids displayed variable haemolytic activity against human
erythrocytes; peptoids 1, 3, 4 and 5 lysed 10% or more of erythrocytes; and peptoids 6, 7
and 9 lysed less than 5% of erythrocytes.
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Based on the initial cytotoxicity data (Figures 2 and 3) peptoids 4 and 9 were 
then tested for efficacy in inhibiting F. nucleatum biofilm formation in 96 well mi-
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4). Interestingly, there did not appear to be enhanced biofilm inhibition at 10 μM versus 
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Figure 2. Percentage lysis of human erythrocytes by peptoids 1–9 (100 µM) compared with positive
control (1% Triton x-100). (***: p < 0.001; *: p < 0.5; ns: p > 0.05). One-way ANOVA followed by
Dunnett’s multiple comparison test. (n = 3 independent experiments, 3 replicates in each).
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2.2. Cytotoxicity of Peptoids against Human Gingival Fibroblasts
In addition to cytolysis of human erythrocytes, peptoids were tested for their effects on
the viability of human primary gingival fibroblasts [30], since these cells are relevant should
peptoids be translated into clinical practice for the treatment of periodontal disease and/or
peri-implantitis. Of the seven peptoids tested (1, 3–7 and 9) all significantly decreased
viability of gingival fibroblasts at concentrations of 10 µM and 100 µM, whereas at a
concentration of 1 µM, peptoids 4 and 9 were shown not to alter gingival fibroblast viability
compared with untreated controls (Figure 3).




Figure 3. Cell viability as determined by MTT assay following treatment of gingival fibroblasts 
with peptoids 1, 3–7 and 9 (1, 10 and 100 µM), (***: p <0.001; **: p< 0.01; ns: p > 0.05). One-way 
ANOVA followed by Dunnett’s multiple comparison test. (n = 3 independent experiments, 6 rep-
licates in each). 
 
Figure 4. F. nucleatum cell numbers in a biofilm inhibition assay, following treatment with 
peptoids 4  and 9 at 1 μM and 10 μM. Cell numbers were measured by propidium mono-
azide(PMA)-qPCR for detection of live cells only (***: p< 0.0005; **: p< 0.05 One-way ANOVA 
followed by Dunnett’s multiple comparison test, n=3 independent experiments, 3 repli-
cates in each). 
Figure 3. Cell viability as determined by MTT ssay f llowing treatment of gingival fibroblasts with
peptoids 1, 3–7 and 9 (1, 10 and 100 µM), (***: p < 0.001; **: p < 0.01; ns: p > 0.05). ne- ay ANOVA
followed by Dunnett’s multiple comparison test. (n = 3 independent experiments, 6 replicates
in each).
2.3. Biofilm Inhibition by Peptoids
Based on the initial cytotoxicity data (Figures 2 and 3) peptoids 4 and 9 were then
tested for efficacy in inhibiting F. nucleatum biofilm formation in 96 well microtitre plates
under anaerobic conditions. Peptoids 4 and 9 showed a statistically significant reduction in
biofilm formation at both 1 µM and 10 µM concentrations (Figure 4). Interestingly, there
did not appear to be enhanced biofilm inhibition at 10 µM versus 1 µM for both peptoids
studied (Figure 4).
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3. Discussion
The family of peptoids studied herein had previously been examined for their cy-
totoxicity against HepG2 epithelial and HaCaT keratinocyte cell lines [10], but had not
been tested for their cytocoxicity against human erythrocytes or primary cells. The ma-
jority of these peptoids (15/18 peptoids tested) previously displayed no toxicity to either
the HepG2 epithelial or HaCaT keratinocyte cell lines at a concentration of 100 µM [10].
Interestingly, however, peptoids 2 and 8 were found to be toxic to both cell lines at concen-
trations between 20–40 µM [10]. In agreement with this finding, we report in the current
study that peptoids 2 and 8 had the highest levels of human erythrocyte haemolysis.
The remaining peptoids 1, 3–7 and 9 were then assessed for their potential effects
on gingival fibroblast viability. These cells have an important role for healing following
infection or surgical incision in the oral cavity. If healing is delayed, it can increase bacterial
seeding onto the implant surface. In oral wounds, fibroblasts start to migrate to the site
within 24 h and begin production of granulation tissue during the early phase of wound
healing [31]. Fibroblasts then produce new connective tissue as well as differentiating
to myo-fibroblasts to allow for wound contraction, the final stage of wound healing,
which is generally completed within 4–8 days [31]. Peptoid 4 (NaeNpheNphe)4-NH2 and
peptoid 9 (NahNspeNspe)3-NH2 were the only members of the peptoid family that did
not significantly reduce cell viability of human gingival fibroblasts at a concentration of
1 µM. Immortalised cell lines have often been used to test the cytotoxicity of potential
therapeutics, including peptoids [10,20], whereas primary cell cultures were used in the
current work. It is well recognised that immortalised cell lines are more resistant to
cytotoxic chemicals than cultured primary cells [32]. Both HepG2 and HaCaT have been
reported to be significantly less sensitive to many toxins [33,34]. This may be the result of
the genetic modifications, and resultant changes in characteristics that enable immortalised
cell lines to be continuously sub-cultured [34]. As a result, it is suggested that immortalised
cell lines are a poor substitute for relevant primary cells in cytotoxicity studies. While
primary cell cultures are short-lived when compared with immortalised cell lines, they
are closer characteristically to native fibroblasts and thus provide a more sensitive in vitro
model for cytotoxicity studies. Our data, employing human primary gingival fibrobalst
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cultures, clearly demonstrate this increased sensitivity and underline the importance of
primary cell cultures in cytotoxicity assays.
Peptoids 4 and 9 showed a statistically significant reduction in F. nucleatum biofilm
formation as determined by propidium monoazide (PMA)-qPCR. The technique of PMA-
qPCR allows quantification of the number of living cells within biofilms. PMA binds
covalently to double-stranded DNA that is not protected by the cell membrane in viable
microbes. DNA bound to PMA will not be quantified by qPCR, and thus the PMA-qPCR
method will quantify viable cells only. PMA-qPCR has advantages over conventional
colony forming unit (CFU) counting techniques because CFU quantification of microbes
within biofilms can significantly underestimate the total live cell count, due to the presence
of ‘viable but non-culturable’ (VBNC) microbes. The VBNC bacterial cells are metabolically
active but do not grow and divide in routine laboratory culture media. It is known
that many species of microbes have the capacity to enter the VBNC state, depending on
external environmental conditions [35], including antimicrobial treatment regimens [36].
Thus, antimicrobial efficacy could be over-estimated by traditional CFU assays if VBNC
microbes are present after treatment, because by definition these cells will not form CFUs
for enumeration. The log10 reductions in biofilms observed following peptoid treatment
therefore represent significantly decreased cell numbers, which if translated in vivo could
allow the host immune system to act more efficiently against the remaining biofilm.
In conclusion, we report the identification of two peptoids with efficacy against
F. nucleatum biofilm formation in vitro. Effective antimicrobial therapy against anaerobes is
particularly important in view of their importance as human pathogens [37], and peptoid
treatment may represent a novel way to reduce disease-causing biofilms.
4. Materials and Methods
4.1. Peptoid Preparation
Peptoids 1–9 (Figure 1), which were previously prepared as described in detail by
Luo et al. [10], were initially screened for their potential cytotoxicity against human ery-
throcytes at a working concentration of 100 µM. All peptoids were soluble in aqueous
solutions. Peptoid stock solutions were prepared in distilled deionized water and subse-
quent diluted in phosphate-buffered saline (PBS) to obtain working concentrations for use
in cytotoxicity and biofilm assays.
4.2. Haemolytic Assay
The haemolytic assay was employed to determine the potential cytotoxicity of the pep-
toids against human red blood cells. Blood samples were collected with ethical approval
and informed consent in vacutainer containers with dipotassium ethylene- diaminete-
traacetic acid (K2-EDTA). Blood was then transferred to a 50 mL tube and centrifuged at
1200× g for 5 min at room temperature. The supernatant was removed and PBS was added
to the original volume of sample obtained. This step was repeated a further 3 times. The
red blood cells were then diluted to 8% of their original volume for use in the haemolytic
assay. A 1% solution of Triton x-100 in PBS served as a positive control, and PBS was used
as a negative control.
Peptoids 1, 2, 3, 4, 5, 6, 7, 8 and 9 were diluted in PBS to 200 µM. A total volume
of 100 µL of each peptoid was placed in the wells of a v-bottomed 96-well microtitre
plate. Red blood cells (100 µL), prepared as outlined above, were then added. The final
peptoid concentration in each well was therefore 100 µM. The plate was sealed with an
adhesive film to prevent evaporation and incubated at 37 ◦C for 1 h. Following this time,
the plate was centrifuged at 4000 RPM for 5 min to pellet unlysed red blood cells. Following
this step, 100 µL of supernatant was carefully removed from each well and added to a
flat-bottomed 96-well microtitre plate. The absorbance was read at 450 nm using a Tecan
Genios (Männedorf, Switzerland) plate reader, and the percentage of red blood cells lysed
was calculated.
Molecules 2021, 26, 4741 7 of 10
4.3. 3-(4,5-Dimethylthiazol-2-yl-2,5-diphenyltetrazolium Bromide (MTT Assay)
Cultured primary gingival fibroblast cells were obtained with ethical approval and
informed consent, and were grown as previously described [30]. Cells were seeded in 96-
well plates at a concentration of 1 × 105 cells/mL (100 µL per well). Plates were incubated
at 37 ◦C for 48 h to allow cells to reach confluence. Peptoids 1, 3, 4, 5, 6, 7 and 9 were
diluted to 200 µM, 20 µM and 2 µM. The culture medium was removed and replaced with
50 µL of Dulbecco’s Modified Eagle’s Medium (DMEM) and 50 µL of the relevant peptoid.
The cells were incubated for 24 h at 37 ◦C. After this time, 10 µL of 3-(4, 5- dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (Sigma-Aldrich, Poole, UK) was
added to each well and the plate was incubated for a further 3 h at 37 ◦C. The medium
was removed by aspiration and the wells were allowed to dry for 20 min. Then, 200 µL of
dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Poole, UK) was added to all wells and the
plate was placed in an incubator for 30 min. The absorbance of the wells was read in a
Tecan Genios (Männedorf, Switzerland) plate reader at 510 nm after 60 s of orbital shaking.
4.4. Biofim Inhibition Assay
The F. nucleatum type strain (NCTC 10562, originally isolated from human, inflamed
gingival tissue) was obtained from the National Collection of Type Cultures. The optical
density (OD) of an overnight culture was measured spectrophotometrically at 570 nm and
diluted with fresh broth to an OD of 0.30–0.35. The culture was further diluted 1 in 50 with
anaerobic broth, giving a final inoculum concentration of approximately 5 × 106 CFU/mL.
A biofilm inhibition assay was undertaken in a 96-well plate format. Peptoids 4 and 9
were added along with the inoculum (90 µL of inoculum in broth and 10 µL of peptoid
solution) to each well, to yield peptoid concentrations of 1 µM and 10 µM. A solution
containing 10 µL of PBS and 90 µL of anaerobic broth acted as an untreated control. Biofilms
were allowed to develop in the presence of peptoids 4 or 9 for 48 h. After 48 h biofilm
development, planktonic cells were removed by gently washing three times with PBS
and then replacing the broth with 100 µL of fresh anaerobic broth prior to a further 48 h
incubation for biofilm maturation. After this time, the wells were gently washed three
times with 100 µL of PBS to remove planktonic cells. Plates were then sealed with parafilm,
and the biofilms were dislodged from the wells in an ultrasonic bath for 20 min. Plates were
then returned to the anaerobic cabinet and the dislodged biofilm samples were collected in
Eppendorf tubes.
4.5. Propidium Monoazide (PMA–Modified) qPCR
Propidium monoazide (PMA)-qPCR was undertaken essentially as previously de-
scribed [38]. Briefly, PMA (Biotium, Fremont, CA, USA), was diluted 1 in 50 with PBS.
The diluted PMA was then added to the dislodged biofilm samples in a 1:1 ratio in an
Eppendorf tube, to give a final PMA concentration of 200 µM. The Eppendorfs were in-
cubated at 37 ◦C for 10 min in the dark and then placed under a broad spectrum LED
floodlight (ELRD, HL60 ˆ0 LEDx Max 0.1V) for 10 min. During this time, the Eppendorfs
were inverted several times. Bacterial DNA was then extracted using the Qiagen blood and
tissue kit (Germantown, MD, USA) according to the manufacturer’s instructions. Briefly,
bacterial samples released from biofilms were centrifuged at 14000 RPM for 6 min, and the
supernatant was removed. Bacterial pellets were resuspended in 200 µL of AL buffer, and
25 µL of proteinase K was added to each Eppendorf. The suspensions were then heated to
56 ◦C for 30 min with shaking. Following this, 200 µL of ethanol was added to each Eppen-
dorf and mixed gently. The contents were placed in fresh spin columns in 2 mL collection
tubes. The spin columns were centrifuged at 8000 RPM for 2 min. The flow-through and
the collection tubes were discarded. The spin columns were placed in fresh collection tubes,
and 500 µL of AW1 buffer was added to each column. The spin columns were centrifuged
at 8000 RPM for 2 min. Again, the flow-through and the collection tubes were discarded.
The spin columns were placed in fresh collection tubes, and 500 µL of AW2 buffer was
added. The spin columns were centrifuged at 16000 RPM for 3 min. The flow-through and
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the collection tubes were discarded. The spin columns were placed in fresh collection tubes,
and 100 µL of AE buffer was added to each. These were incubated at room temperature
for 1 min. The tubes were then centrifuged at 8000 RPM for 1 min. The extracted DNA
samples were then transferred to DNase-free Eppendorfs. Finally, qPCR was undertaken
using F. nucleatum specific primers (Table 1), using the reaction formulations detailed in
Table 2 and the reaction conditions outlined in Table 3.
Table 1. Primer sequences for F. nucleatum.
Sequence
F. nucleatum Forward Primer CAACCATTACTTTAACTCTACCATGTTCA
F. nucleatum Reverse Primer GTTGACTTTACAGAAGGAGATTATGTAAAAATC





Lightcycler 480 SYBR Green I Master (x2) 5 µL X1
Forward Primer (10 µM) 0.1 µL 100 nM
Reverse Primer (10 µM) 0.1 µL 100 nM
Nuclease free water 3.6 µL
DNA template 1.2 µL
Total Reaction Volume 10 µL
Table 3. qPCR reaction conditions for F. nucleatum.
Cycles Temperature Hold Time
1 95 ◦C 5 min
65 95 ◦C 10 s
65 55 ◦C 10 s
65 72 ◦C 10 s
Melt analysis
1 95 ◦C 5 s
1 96 ◦C 1 min
1 97 ◦C 1 min
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